2026-23005Proposed RuleWallet

FDA May Downgrade Cancer Tests From Class III to II

Published Date: 11/12/2026

Proposed Rule

Summary

The FDA wants to change the rules for certain cancer test systems called immunohistochemistry (IHC) tests. These tests will move from a strict, expensive approval process (Class III) to a simpler, faster one (Class II) with special safety rules. This change affects companies making these tests and could speed up getting them to doctors and patients. Comments on this plan are open until January 11, 2027.

Analyzed Economic Effects

6 provisions identified: 5 benefits, 1 costs, 0 mixed.

IHC Oncology Tests Moved to Class II

FDA proposes to reclassify immunohistochemistry (IHC) test systems indicated for use with a corresponding approved oncology therapeutic product from class III (premarket approval) to class II (special controls) subject to premarket notification (510(k)). The proposal explicitly lists product codes MVC, NKF, QQT, NQF, PLS, PKW, QUL, QNH, QZJ, SBL, SER, and SHF as the devices affected.

510(k) Required Before Marketing

If the proposed order is finalized, persons who intend to market these oncology therapeutic IHC-based test systems must submit a premarket notification under section 510(k) of the FD&C Act and receive clearance prior to marketing the device. FDA is not proposing to exempt this device type from 510(k) requirements.

May Speed Patient Access to Tests

FDA states the reclassification to class II and use of the 510(k) pathway is less burdensome and generally results in a shorter premarket review timeline than a PMA, which FDA expects may provide more timely patient access and enable more manufacturers to develop these tests.

Existing PMA Devices Keep Authorization

Oncology therapeutic IHC-based test systems that have prior PMA approval at the time of the final order may continue to be marketed under their existing PMA and would not require an additional marketing authorization. However, changes or modifications that could significantly affect safety or effectiveness would generally require submission of a 510(k).

Use of Predetermined Change Control Plans

FDA notes manufacturers may use predetermined change control plans (PCCPs) authorized by FDA to implement future modifications described in the PCCP without submitting a new 510(k) for each change, under section 515C of the FD&C Act as added by FDORA. FDA reviews a PCCP as part of a marketing submission to ensure continued safety and effectiveness.

Devices Identified as Prescription IVDs

Under the proposed order, oncology therapeutic IHC-based test systems would be identified as prescription in vitro diagnostic (IVD) devices and would be subject to prescription labeling requirements for IVD products (see 21 CFR 809.10(a)(4) and (b)(5)(ii)).

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Comments Due
11/12/2026
1/11/2027

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register